An Open-Label Study to Evaluate Retreatment With LIPO-202

Neothetics

Status and phase

Unknown

Phase 2

Conditions

Central Abdominal Bulging

Treatments

Drug: LIPO-202

Study type

Interventional

Funder types

Industry

Identifiers

NCT02397525

LIPO-202-CL-22

Details and patient eligibility

About

Evaluate the safety of three 8-week courses of treatment with LIPO-202 in non-obese patients who have central abdominal bulging. Efficacy measurements will also be collected.

Enrollment

150 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Provided consent
Healthy male or non-pregnant female subjects
BMI < 30 kg/m2
Stable diet and exercise routine
Central abdominal bulging that is at least "Slight Bulge, Not Flat"

Exclusion criteria

Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen
Plan on starting a weight loss or exercise program during the study.
Be a woman who is pregnant, breast feeding, have had a baby within 6 months and/or not using appropriate birth control.
Known hypersensitivity to study drugs
Prior or current enrollment in any Neothetics (formerly Lithera) study involving LIPO-102 or LIPO-202